2018 Second Quarter and R&D update
We announced our second quarter 2018 results on Wednesday 25 July and hosted an investor event where Emma Walmsley, CEO, and Simon Dingemans, CFO, spoke about our performance and financial outlook, and Hal Barron, Chief Scientific Officer and President, R&D, presented our R&D update.
- Q2 2018 results and R&D update announcement PDF - 1.0MB
- Q2 2018 slides - Emma Walmsley PDF - 495.7KB
- Q2 2018 slides - Simon Dingemans PDF - 131.7KB
- R&D update slides - Hal Barron PDF - 1.9MB
- Q2 2018 results transcript - Part 1 PDF - 188.4KB
- Q2 2018 results transcript - Part 2 PDF - 242.3KB
- Q2 2018 results infographic PDF - 556.7KB
- Q2 2018 US dollar translation PDF - 131.6KB
- Q2 2018 pre announcement aide memoire PDF - 742.2KB
2017 Full year and fourth quarter
We announced our full year and fourth quarter 2017 results on Wednesday 7 February.
2017 Third Quarter
We announced our third quarter 2017 results on Wednesday 25 October.
Q2 2017 and investor event
We announced our second quarter 2017 results on 26 July and hosted an investor event where Emma Walmsley, CEO, and Simon Dingemans, CFO, spoke about our strategic priorities and financial outlook.
- Q2 2017 results announcement PDF - 1.9MB
- Q2 2017 results video transcript PDF - 177.6KB
- Q2 2017 US dollar translation PDF - 121.7KB
- Q2 2017 results infographic PDF - 862.6KB
- Q2 2017 pre announcement aide memoire PDF - 795.1KB
- Emma Walmsley slides: Key priorities PDF - 864.3KB
- Simon Dingemans slides: Q2 and financial outlook PDF - 509.3KB
- Investor event full transcript PDF - 173.6KB
Other key information
Speeches & presentations
Search through our archive of speeches and presentations from conferences and events
Keep up to date with our news and recent announcements
A snapshot of our medicines and vaccines currently in development across three stages: phase I, phase II and phase III